Amiloid Cardiomyopathies: Clinical, Diagnostic and Therapeutic Aspects, An Issue of Heart Failure Clinics
- 1st Edition, Volume 20-3 - June 7, 2024
- Imprint: Elsevier
- Editors: Giuseppe Limongelli, Michele Emdin, Marco Merlo, Emanuele Monda
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 2 1 4 3 - 2
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 2 1 4 4 - 9
In this issue of Heart Failure Clinics, guest editors Drs. Giuseppe Limongelli, Michele Emdin, Marco Merlo, and Claudio Rapezzi bring their considerable expertise to the topic… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteIn this issue of Heart Failure Clinics, guest editors Drs. Giuseppe Limongelli, Michele Emdin, Marco Merlo, and Claudio Rapezzi bring their considerable expertise to the topic of Amyloid Cardiomyopathies: Clinical, Diagnostic and Therapeutic Aspects. Top experts in the field discuss the role of clinical use of biomarkers in cardiac amyloidosis; cardiac magnetic resonance in the management of cardiac amyloidosis; bone scintigraphy: strength points and pitfalls in the diagnosis of ATTR-cardiac amyloidosis; PET and cardiac amyloidosis; endomyocardial biopsy in the diagnosis of cardiac amyloidosis; and much more.
- Contains 17 relevant, practice-oriented topics including the changing epidemiology of cardiac amyloidosis; arrhythmic stratification of cardiac amyloidosis: state of the art; specific therapy in ATTR-related cardiomyopathy: future perspectives beyond tafamidis; and more.
- Provides in-depth clinical reviews on amyloid cardiomyopathies, offering actionable insights for clinical practice.
- Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
Heart Failure Cardiologists
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Forthcoming Issues
- Preface
- Amyloidosis and Amyloidogenesis: One Name, Many Diseases
- Key points
- Introduction
- Amyloidogenesis and pathophysiology
- Main precursors and types of cardiac amyloidosis
- Light Chain amyloidosis
- Wild-type transthyretin amyloidosis
- Variant transthyretin amyloidosis
- Serum Amyloid A amyloidosis
- Beta2-macroglobulin amyloidosis
- Gelsolin amyloidosis
- Fibrinogen amyloidosis
- Apoliporotein AI, AII and AIV amyloidosis
- Summary
- Clinics care points
- Pathophysiology of Cardiac Amyloidosis
- Key points
- Introduction
- Amyloid formation and deposition
- Cardiac involvement
- Mechanical and cytotoxic damage
- Summary
- Clinics care points
- The Role of Echocardiography for the Clinical Diagnosis, Risk Stratification, and Management of Cardiac Amyloidosis
- Key points
- Introduction
- “Basic” echocardiographic evaluation and red flags detection
- Advanced echocardiographic evaluation and red flags detection
- Right ventricular involvement: relevance in diagnosis, risk stratification and management
- Echo scores to predict cardiac amyloidosis
- Summary
- Clinics care points
- Clinical Use of Biomarkers in Cardiac Amyloidosis
- Key points
- Introduction
- Biomarkers in amyloidosis
- Biomarkers of organ damage
- Biomarkers of amyloidogenic process
- Biomarkers in prognostic stratification
- Prognostic stratification in light chain
- Prognostic stratification in ATTR
- Biomarkers in orienting treatment strategies in light chain amyloidosis
- Cardiac biomarkers for assessment of treatment response
- Imaging biomarkers of cardiac amyloid infiltration
- Future perspectives
- Cardiovascular Magnetic Resonance in the Management of Cardiac Amyloidosis: Current and Future Clinical Applications
- Key points
- Introduction
- Anatomic and functional assessment
- T1 and T2 mapping
- Perfusion
- Late gadolinium enhancement
- Extracellular volume mapping
- Use of cardiac magnetic resonance according to current recommendations
- Summary
- Clinics care points
- The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis
- Key points
- Introduction
- Diagnostic accuracy of myocardial uptake of bone tracers
- Scintigraphy-based noninvasive diagnosis of cardiac amyloidosis
- Head-to-head comparison of bone tracers
- Prognostic value of cardiac scintigraphy with bone tracers
- Clinical significance of Perugini 1 grade
- Summary
- Clinics care points
- Genotype-Phenotype Correlations in ATTR Amyloidosis: A Clinical Update
- Key points
- Introduction
- Summary
- Clinics care points
- Standard Therapy in Cardiac Amyloidosis: What is Known, What is “Gray”
- Key points
- Introduction
- Prevalence of cardiac amyloidosis in patients with heart failure
- Pathogenesis of heart failure in cardiac amyloidosis
- Standard management of heart failure patients with cardiac amyloidosis
- Management of genotype-positive phenotype-negative carriers
- Summary
- Clinics care points
- Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones
- Key points
- Introduction
- Tafamidis: mechanism of action and pharmacokinetics
- Efficacy of tafamidis in the treatment of ATTR-related cardiomyopathy
- Indications and gray zones in the clinical use of tafamidis
- Comparison of Tafamidis with Other Treatment Modalities
- Summary
- Specific Therapy in Transthyretin Amyloid Cardiomyopathy: Future Perspectives Beyond Tafamidis
- Key points
- The long journey from circulating transthyretin to amyloid fibril
- Small interfering RNAs
- Antisense oligonucleotides
- Editing the transthyretin gene in hepatocytes
- Monoclonal antibodies for depletion of cardiac transthyretin amyloid
- Antibody-associated reversal of transthyretin amyloid
- Summary and future perspectives
- Edition: 1
- Volume: 20-3
- Published: June 7, 2024
- Imprint: Elsevier
- No. of pages: 240
- Language: English
- Hardback ISBN: 9780443121432
- eBook ISBN: 9780443121449
GL
Giuseppe Limongelli
Affiliations and expertise
University of Campania “Luigi Vanvitelli” Monaldi Hospital,ME
Michele Emdin
Affiliations and expertise
Institute of Life Sciences, Scuola Superiore Sant’Anna, Pisa, Italy, Fondazione Toscana G. Monasterio, CNR-Regione ,ToscanaMM
Marco Merlo
Affiliations and expertise
Institute of Life Sciences, Scuola Superiore , Sant’Anna, Pisa, Italy, Fondazione Toscana G. Monasterio, CNR-Regione ,Toscana,EM
Emanuele Monda
Affiliations and expertise
Department of Translational Medical Sciences, University of Campania, Naples, Italy